For menopausal hormone therapy, most clinicians aim for a blood estradiol level between 60 and 150 pg/mL. For feminizing gender-affirming hormone therapy, the target is typically 100 to 200 pg/mL. Where you fall within those ranges depends on your symptoms, your goals, and how your body absorbs and processes the estrogen you’re taking.
These numbers refer specifically to estradiol (E2), the most potent form of estrogen and the one your provider should be measuring. “Total estrogen” or estrone (E1) levels are less useful for gauging whether your dose is working. When you get blood work, make sure the result you’re looking at says estradiol.
Target Levels for Menopausal HRT
The widely cited clinical target for postmenopausal women on HRT is 60 to 150 pg/mL of estradiol. But within that range, your experience can differ significantly depending on where your level lands.
At the lower end, around 60 pg/mL, about half of women get meaningful relief from hot flashes, and bone loss begins to slow. That 60 pg/mL threshold is considered the minimum needed to protect bone density. Below it, markers of bone breakdown remain elevated. At around 100 pg/mL, hot flashes are essentially eliminated for most women, and bone density can actually increase rather than just hold steady.
So if your level is 65 pg/mL and you’re still having several hot flashes a day, that doesn’t mean HRT isn’t working for you. It may mean your level needs to be higher within the target range. The goal isn’t to hit one magic number. It’s to find the level that resolves your specific symptoms while staying within a range that’s considered safe.
Target Levels for Feminizing Hormone Therapy
For transgender women and transfeminine individuals on gender-affirming hormone therapy, the Endocrine Society and WPATH guidelines recommend targeting estradiol levels of 100 to 200 pg/mL. Alongside that, testosterone should fall below 50 ng/dL.
These two numbers work together. Estradiol in the right range helps suppress testosterone production on its own, though many people also take an anti-androgen. If your estradiol is in range but your testosterone remains high, or vice versa, your provider will likely adjust your regimen. Physical feminization, including breast development, fat redistribution, and skin changes, depends on both hormones reaching their targets and staying there consistently over months and years.
How Delivery Method Affects Your Levels
The way you take estrogen changes what happens in your bloodstream, even at equivalent doses. This matters because the number on your lab report doesn’t tell the whole story if you don’t know what form you’re using.
Oral estradiol (pills) passes through the liver before reaching the rest of your body. This “first pass” effect converts a large portion of estradiol into estrone, a weaker form of estrogen. The result is that your estrone-to-estradiol ratio can be five times higher than what your body would produce naturally. Your estradiol reading might look modest while your total estrogen exposure is actually quite high.
Transdermal estradiol (patches, gels, sprays) absorbs through the skin and enters your bloodstream directly, bypassing the liver. This produces an estrone-to-estradiol ratio that more closely matches what premenopausal ovaries produce. A lower dose achieves similar blood levels, and the overall hormone profile is more physiologic. This is one reason many providers prefer transdermal delivery, especially for people with clotting risk factors or liver concerns.
If you switch from pills to patches or gels, your estradiol number may look different even if your symptom relief stays the same. Your provider should interpret your lab results in the context of your delivery method.
Why Your Levels May Not Match Someone Else’s
Two people on the same dose, using the same patch or pill, can end up with very different blood levels. Body composition, skin thickness, application site, metabolism, and even the time of day blood is drawn all influence the result. With transdermal products in particular, absorption varies from person to person and even from day to day.
A cross-sectional study of postmenopausal women using transdermal estradiol in real-world settings found wide variation in serum levels despite standardized prescribing. This is normal, and it’s why monitoring matters. A single blood draw gives you a snapshot, not a full picture. If your level seems low but your symptoms are well controlled, that may be fine. If your level looks adequate on paper but you still feel terrible, your provider may adjust upward or switch formulations.
When and How to Test
For oral estradiol, blood is usually drawn about 12 hours after your last dose, which means taking your pill at night and getting labs in the morning works well. For patches, labs can be drawn anytime during the wear period, though many providers prefer testing on day two or three of a twice-weekly patch, when levels are relatively stable. For gels and creams, drawing blood before applying your daily dose gives a trough reading, which is the most useful for comparison over time.
Testing frequency varies. Many providers check levels around 6 to 12 weeks after starting HRT or changing a dose, then annually once things stabilize. If you’re not getting the symptom relief you expected, asking for a level check sooner is reasonable. The number alone doesn’t dictate treatment, but it gives you and your provider a shared reference point for making adjustments.
What the Numbers Mean in Practice
For context, premenopausal estradiol levels fluctuate dramatically throughout the menstrual cycle, ranging from about 30 pg/mL during a period to over 300 pg/mL around ovulation. After menopause, levels typically drop below 20 pg/mL. HRT doesn’t aim to replicate the peaks of a natural cycle. It aims to maintain a steady level in the range that controls symptoms and protects bone.
If your level is below 60 pg/mL, you’re likely underdosed for both symptom relief and bone protection. Between 60 and 100 pg/mL, you may have partial symptom relief. Above 100 pg/mL, most menopausal symptoms resolve. Levels consistently above 200 pg/mL in menopausal HRT are generally higher than necessary and may prompt your provider to reduce the dose, though the clinical ceiling depends on individual risk factors.
For feminizing HRT, staying in the 100 to 200 pg/mL range balances effective feminization with safety. Levels above 200 pg/mL don’t necessarily speed up physical changes and can increase the risk of blood clots, particularly with oral estradiol.